AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Abcelera's full year 2025 business update conference call. My name is Chelsea and I will facilitate the audio portion of today's interactive broadcast. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. To withdraw your question, press star one again. At this time, I would like to turn the call over to Trin Stimart, Abcelera's Chief Legal and Compliance Officer. You may proceed. Thank you. Hello, everyone, and thank you for joining us today for Abcelera's full year 2025 earnings call. I'm Trin Stimart, Abcelera's Chief Legal and Compliance Officer. Dr. Carl Hansen, Abcelera's President and CEO, and Andrew Booth, Abcelera's Chief Financial Officer, will be speaking on today's call. Also, Sarah Noonberg, our Chief Medical Officer, is on the call with us. During this call, we may make projections and forward-looking statements based on our current expectations and in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially due to factors as outlined in our latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Abcelera is not obligated to update any forward-looking statements, whether due to new information, future events, or otherwise. Our presentation today, our earnings press release, and our SEC filings are available on our investor relations website. The information we provide about our pipeline is intended for the investment community and is not promotional. As we transition to our prepared remarks, please note that all dollars mentioned during the call are U.S. dollars. After our prepared remark...